-
公开(公告)号：US09850307B2
公开(公告)日：2017-12-26
申请号：US14843250
申请日：2015-09-02
申请人： Glaxo Group Limited
CPC分类号： C07K16/2863 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N1/00 , C12N15/09
摘要： The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.
-
公开(公告)号：US20150361176A1
公开(公告)日：2015-12-17
申请号：US14843250
申请日：2015-09-02
申请人： Glaxo Group Limited
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N1/00 , C12N15/09
摘要： The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.
摘要翻译： 本公开提供了抗TGFbetaRII免疫球蛋白单可变结构域。 适当地，根据本公开内容的抗TGFbetaRII免疫球蛋白单可变结构域是具有SEQ ID NO：1-28中任一项所述的具有多达5个氨基酸取代，缺失或添加的氨基酸序列的抗TGFbetaRII免疫球蛋白单可变结构域。 本公开进一步提供了用于治疗与TGFbeta信号传导相关疾病的合适的多肽和药物组合物，并适当地选自以下组中的疾病：组织纤维化，例如肺纤维化，包括特发性肺纤维化; 肝纤维化，包括肝硬化和慢性肝炎; 类风湿关节炎; 眼部疾病; 皮肤纤维化，包括皮肤瘢痕疙瘩; Dupuytren的挛缩 肾纤维化如肾炎和肾硬化; 伤口愈合; 疤痕减少 和血管病变，如再狭窄。
-
公开(公告)号：US20180086835A1
公开(公告)日：2018-03-29
申请号：US15818861
申请日：2017-11-21
申请人： Glaxo Group Limited
CPC分类号： C07K16/2863 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N1/00 , C12N15/09
摘要： The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.
-
-
搜索结果
3 条记录 (耗时 0.021 秒)
